## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.0% below STRENGTH zone (3.0-6.0%); PEG 6.41 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($358.05)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Form DEF 14A BECTON DICKINSON & CO For: Dec 12**
- Source: StreetInsider | 20251218T160751 | Somewhat-Bullish | Relevance: 74%
- Becton, Dickinson and Company filed its DEF 14A proxy statement for December 12, outlining proposals for its 2026 Annual Meeting including director elections, ratification of auditors, and executive compensation approval. The company also seeks approval for an amendment to its 2004 Employee and Director Equity-Based Compensation Plan to increase available shares. The document details BD's financial performance, strategic transformation, and governance practices, emphasizing alignment of executive pay with long-term shareholder value.

**2. Will Brukerâ€™s (BRKR) AbCellera Settlement and Beacon Royalties Deal Change Its Investment Narrative?**
- Source: Simply Wall Street | 20251219T070852 | Neutral | Relevance: 63%
- Bruker Corporation recently settled a patent dispute with AbCellera, agreeing to pay $36 million upfront plus ongoing royalties on its Beacon Optofluidic platform sales. This settlement removes legal uncertainty and clarifies future economics for Bruker, although the company's investment narrative still largely depends on a recovery in demand for its research tools and life science platforms. Despite this positive development, investors should remain aware of potential challenges from prolonged weaknesses in global academic and biopharma funding.

**3. Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?**
- Source: www.sharewise.com | 20251218T150930 | Neutral | Relevance: 60%
- The Invesco S&P 500 Equal Weight Health Care ETF (RSPH), launched in 2006, offers broad exposure to the Health Care sector through a smart-beta equal-weighting strategy. With over $751.81 million in assets and an expense ratio of 0.40%, RSPH aims to provide better risk-return performance compared to traditional market-cap-weighted indexes. The ETF holds 63 stocks, with top holdings including Waters Corp, Cardinal Health Inc, and Eli Lilly & Co, and has shown an 8.84% return year-to-date and 7.46% over the last year.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $415 | $385 | +8% |
| 2025-12-10 | Wolfe Research | $480 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $423 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-10 | Wolfe Research | up | Outperform |
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.9% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 6.4x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 6.41 signals overvaluation risk, limited margin of safety. Forward P/E 26.4x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Analyst sentiment positive (1 raises, avg +8%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.5B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.41 |
| Forward P/E | 26.4 |
| Current P/E | 28.8 |
| YoY Growth | 9.0% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.1% to -2.0% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.0pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). MACD histogram bearish (-3.98), momentum weakening. RSI neutral at 45. OFD pattern: +SLH (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.97% (CS: 22) | Neutral |
| RSI_14 | 45.3 | Neutral |
| MACD Histogram | -3.98 | Bearish |
| vs SMA20 | 0.962x | Below |
| vs SMA50 | 1.016x | Above |
| vs SMA200 | 1.113x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $377.67
- **Stop Loss:** $358.05 (5.2% risk)
- **Target:** $397.29 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 61
- **Position Value:** $23,037.87
- **Portfolio %:** 23.04%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*